戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ctivation of ATF4 during the pathogenesis of medullary thyroid cancer.
2 eted medical therapies are now available for medullary thyroid cancer.
3 n life for RET mutation carriers at risk for medullary thyroid cancer.
4 tient (0.6%) died from incidentally detected medullary thyroid cancer.
5 es has been advocated for early detection of medullary thyroid cancer.
6 on in a family with hereditary renal and non-medullary thyroid cancer.
7 dic counterpart, but is less aggressive than medullary thyroid cancer.
8 (ab)2 with AHSCR in patients with metastatic medullary thyroid cancer.
9 patients with rapidly progressing metastatic medullary thyroid cancer.
10 MET in addition to VEGFR and is approved for medullary thyroid cancer.
11 ers without clinical disease before age 6 in medullary thyroid cancer and MEN type IIA, and as soon a
12 a role in Ras and Raf signal transduction in medullary thyroid cancer and other cells.
13 -degree relatives with histologically proven medullary thyroid cancer and phaeochromocytoma.
14 s cabozantinib (FDA-approved for progressive medullary thyroid cancer) and PF-04217903 block their ac
15                                              Medullary thyroid cancer arises from calcitonin-producin
16 size to the uveal tract, even after decades; medullary thyroid cancer can be part of multiple endocri
17 their antiproliferative efficacy against the medullary thyroid cancer cell line TT.
18 es a program of differentiation in the human medullary thyroid cancer cell line TT.
19                 Knockdown of RET by shRNA in medullary thyroid cancer-derived cells stimulated expres
20         At comparable masses, colorectal and medullary thyroid cancers had significantly higher tumor
21 nts that are approved for differentiated and medullary thyroid cancers have prolonged progression-fre
22                            The prevention of medullary thyroid cancer in patients with multiple endoc
23  from a genome-wide association study of non-medullary thyroid cancer, including in total 3,001 patie
24                            RET inhibition in medullary thyroid cancer is also being explored.
25                                     Familial medullary thyroid cancer may occur in isolation or as pa
26                                     Familial medullary thyroid cancer (MTC) and its precursor, C cell
27                                              Medullary thyroid cancer (MTC) can be caused by germline
28                                              Medullary thyroid cancer (MTC) cells characteristically
29                    We have found, with human medullary thyroid cancer (MTC) cells, that activated Ras
30 ity of nonendocrine manifestations preceding medullary thyroid cancer (MTC) for early diagnosis of mu
31 onstrated clinical activity in patients with medullary thyroid cancer (MTC) in phase I.
32 tory differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC) in the past 10 years.
33                                              Medullary thyroid cancer (MTC) is an uncommon malignancy
34                                              Medullary thyroid cancer (MTC) is derived from the paraf
35 s institutional study aimed at quantifying a medullary thyroid cancer (MTC) patient's risk of lung, l
36 l blood stem cell (PBSC) support in advanced medullary thyroid cancer (MTC) patients.
37 oring the prospects of a cure for persistent medullary thyroid cancer (MTC) stratified by basal calci
38 ll provide an update of important studies in medullary thyroid cancer (MTC) with an emphasis on targe
39 sess the targeting of established and occult medullary thyroid cancer (MTC) with radiolabeled monoclo
40 f cabozantinib, which included patients with medullary thyroid cancer (MTC), led to expansion of an M
41  tumors including small cell lung cancer and medullary thyroid cancer (MTC).
42 nresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
43 etastatic papillary thyroid cancer (PTC) and medullary thyroid cancer (MTC).
44 activity are critical in the pathogenesis of medullary thyroid cancer (MTC).
45 ttee on Cancer (AJCC) TNM staging system for medullary thyroid cancer (MTC).
46 EN1) and MEN2 syndromes in humans, including medullary thyroid cancer (MTC).
47 abeled NP-4 and MN-14 anti-CEA antibodies in medullary thyroid cancer (MTC).
48 ged as a promising target for the therapy of medullary thyroid cancers (MTC) and of a subset of papil
49 an arise from parafollicular cells (familial medullary thyroid cancer) or from follicular cells (fami
50 lorectal, 9 lung, 7 pancreas, 6 breast and 4 medullary thyroid cancer patients), mostly in very advan
51 ts (8 colorectal, 3 lung, 1 pancreatic and 1 medullary thyroid cancer) received RAIT with 131I-NP-4 F
52 ycaemia, pancreatitis, pancreatic cancer, or medullary thyroid cancer reported between GLP-1 receptor
53 t breast cancers, non-Hodgkin lymphomas, and medullary thyroid cancers represent novel indications fo
54          The discovery of a locally advanced medullary thyroid cancer that is not amenable to surgery
55                                     One of 5 medullary thyroid cancers was positive with the agonist,
56 tients having minimal disease, as well as in medullary thyroid cancer, where cytotoxic tumor doses mi
57 ment and treatment of patients with advanced medullary thyroid cancer with emphasis on current target

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。